INVO Bioscience Obtains Regulatory Approval to Commercialize INVOcell In Thailand

Dec 1, 2021 | Press Releases

INVO’s distribution partner, IVF Envimed Company Ltd., set to begin commercialization of the INVOcell system within Thailand.SARASOTA, Fla., Dec. 1, 2021 — INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the...

INVO Bioscience Reports Third Quarter 2021 Financial and Operating Results and Provides Business Update

Nov 15, 2021 | Press Releases

Company to Host Conference Call Today at 4:30pm ET (Details Below)SARASOTA, Fla., Nov. 15, 2021 — INVO Bioscience, Inc. (Nasdaq: INVO) (“INVO” or the “Company”), a medical device company focused on creating alternative treatments for...

INVO Bioscience to Report Third Quarter 2021 Financial Results on Monday, November 15, 2021

Nov 9, 2021 | Press Releases

Financial results to be released after market close; Conference call to be conducted at 4:30 pm ETSARASOTA, Fla., Nov. 9, 2021 — INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the world’s only in vivo Culture...

INVO Bioscience Regains Full U.S. Commercialization Rights

Nov 8, 2021 | Press Releases

SARASOTA, Fla., Nov. 8, 2021 — INVO Bioscience, Inc. (“INVO” or the “Company”) (NASDAQ: INVO), a medical device company focused on commercializing the world’s only in vivo culture system (IVC), today announced it will regain full...

INVO Bioscience Announces Four Individual Poster Abstracts Discussing the Benefits of INVOcell Presented at the 2021 American Society for Reproductive Medicine (ASRM) Congress & Expo

Oct 20, 2021 | Press Releases

SARASOTA, Fla. and BALTIMORE, Oct. 20, 2021 — INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the world’s only in vivo Intravaginal Culture System (IVC), INVOcell®, an effective and affordable treatment for...